These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 19320563

  • 1. Potent antitumor effect of interleukin-24 gene in the survivin promoter and retinoblastoma double-regulated oncolytic adenovirus.
    Zhang KJ, Wang YG, Cao X, Zhong SY, Wei RC, Wu YM, Yue XT, Li GC, Liu XY.
    Hum Gene Ther; 2009 Aug; 20(8):818-30. PubMed ID: 19320563
    [Abstract] [Full Text] [Related]

  • 2. The antitumor efficacy of IL-24 mediated by E1A and E1B triple regulated oncolytic adenovirus.
    Xiao LL, Wu YM, Qian J, Tan Y, Xie GL, Zhang KJ, Wang YG, Jia XY, Liu XY.
    Cancer Biol Ther; 2010 Aug 01; 10(3):242-50. PubMed ID: 20574150
    [Abstract] [Full Text] [Related]

  • 3. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
    Li B, Liu X, Fan J, Qi R, Bo L, Gu J, Qian Q, Qian C, Liu X.
    J Gene Med; 2006 Oct 01; 8(10):1232-42. PubMed ID: 16900558
    [Abstract] [Full Text] [Related]

  • 4. Tumor suppressor in lung cancer-1 (TSLC1) mediated by dual-regulated oncolytic adenovirus exerts specific antitumor actions in a mouse model.
    Lei W, Liu HB, Wang SB, Zhou XM, Zheng SD, Guo KN, Ma BY, Xia YL, Tan WS, Liu XY, Wang YG.
    Acta Pharmacol Sin; 2013 Apr 01; 34(4):531-40. PubMed ID: 23503473
    [Abstract] [Full Text] [Related]

  • 5. Complete eradication of hepatomas using an oncolytic adenovirus containing AFP promoter controlling E1A and an E1B deletion to drive IL-24 expression.
    Zhang KJ, Zhang J, Wu YM, Qian J, Liu XJ, Yan LC, Zhou XM, Xiao RJ, Wang YG, Cao X, Wei N, Liu XR, Tang B, Jiao XY, Chen K, Liu XY.
    Cancer Gene Ther; 2012 Sep 01; 19(9):619-29. PubMed ID: 22790965
    [Abstract] [Full Text] [Related]

  • 6. Overexpression of tumor suppressor TSLC1 by a survivin-regulated oncolytic adenovirus significantly inhibits hepatocellular carcinoma growth.
    He G, Lei W, Wang S, Xiao R, Guo K, Xia Y, Zhou X, Zhang K, Liu X, Wang Y.
    J Cancer Res Clin Oncol; 2012 Apr 01; 138(4):657-70. PubMed ID: 22237452
    [Abstract] [Full Text] [Related]

  • 7. HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for liver cancer as a cancer targeting gene-viro-therapy strategy.
    Xu HN, Huang WD, Cai Y, Ding M, Gu JF, Wei N, Sun LY, Cao X, Li HG, Zhang KJ, Liu XR, Liu XY.
    Mol Cancer; 2011 Nov 01; 10():133. PubMed ID: 22040050
    [Abstract] [Full Text] [Related]

  • 8. A novel oncolytic adenovirus based on simian adenovirus serotype 24.
    Cheng T, Song Y, Zhang Y, Zhang C, Yin J, Chi Y, Zhou D.
    Oncotarget; 2017 Apr 18; 8(16):26871-26885. PubMed ID: 28460470
    [Abstract] [Full Text] [Related]

  • 9. Gene-viro-therapy targeting liver cancer by a dual-regulated oncolytic adenoviral vector harboring IL-24 and TRAIL.
    Liu X, Cao X, Wei R, Cai Y, Li H, Gui J, Zhong D, Liu XY, Huang K.
    Cancer Gene Ther; 2012 Jan 18; 19(1):49-57. PubMed ID: 21979578
    [Abstract] [Full Text] [Related]

  • 10. A novel oncolytic adenovirus expressing Escherichia coli cytosine deaminase exhibits potent antitumor effect on human solid tumors.
    Zhang J, Wei F, Wang H, Li H, Qiu W, Ren P, Chen X, Huang Q.
    Cancer Biother Radiopharm; 2010 Aug 18; 25(4):487-95. PubMed ID: 20735209
    [Abstract] [Full Text] [Related]

  • 11. Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma.
    Wei RC, Cao X, Gui JH, Zhou XM, Zhong D, Yan QL, Huang WD, Qian QJ, Zhao FL, Liu XY.
    Hum Gene Ther; 2011 Sep 18; 22(9):1109-19. PubMed ID: 21361790
    [Abstract] [Full Text] [Related]

  • 12. A novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC models.
    Zhang J, Lai W, Li Q, Yu Y, Jin J, Guo W, Zhou X, Liu X, Wang Y.
    Biochem Biophys Res Commun; 2017 Sep 16; 491(2):469-477. PubMed ID: 28698142
    [Abstract] [Full Text] [Related]

  • 13. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
    Wang H, Wei F, Li H, Ji X, Li S, Chen X.
    Int J Mol Med; 2013 Feb 16; 31(2):377-85. PubMed ID: 23229955
    [Abstract] [Full Text] [Related]

  • 14. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
    Jakubczak JL, Ryan P, Gorziglia M, Clarke L, Hawkins LK, Hay C, Huang Y, Kaloss M, Marinov A, Phipps S, Pinkstaff A, Shirley P, Skripchenko Y, Stewart D, Forry-Schaudies S, Hallenbeck PL.
    Cancer Res; 2003 Apr 01; 63(7):1490-9. PubMed ID: 12670895
    [Abstract] [Full Text] [Related]

  • 15. An armed oncolytic adenovirus ZD55-IL-24 combined with ADM or DDP demonstrated enhanced antitumor effect in lung cancer.
    Zhong S, Yu D, Wang Y, Qiu S, Wu S, Liu XY.
    Acta Oncol; 2010 Apr 01; 49(1):91-9. PubMed ID: 19734998
    [Abstract] [Full Text] [Related]

  • 16. Gene therapy targeting hepatocellular carcinoma by a dual-regulated oncolytic adenovirus harboring the focal adhesion kinase shRNA.
    Gao Y, Zhu Y, Huang X, Ai K, Zheng Q, Yuan Z.
    Int J Oncol; 2015 Aug 01; 47(2):668-78. PubMed ID: 26081241
    [Abstract] [Full Text] [Related]

  • 17. Therapeutic efficacy of an hTERT promoter-driven oncolytic adenovirus that expresses apoptin in gastric carcinoma.
    Liu L, Wu W, Zhu G, Liu L, Guan G, Li X, Jin N, Chi B.
    Int J Mol Med; 2012 Oct 01; 30(4):747-54. PubMed ID: 22842823
    [Abstract] [Full Text] [Related]

  • 18. Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus.
    Dong F, Wang L, Davis JJ, Hu W, Zhang L, Guo W, Teraishi F, Ji L, Fang B.
    Clin Cancer Res; 2006 Sep 01; 12(17):5224-30. PubMed ID: 16951242
    [Abstract] [Full Text] [Related]

  • 19. Viral genome DNA/lipoplexes elicit in situ oncolytic viral replication and potent antitumor efficacy via systemic delivery.
    Kwon OJ, Kang E, Kim S, Yun CO.
    J Control Release; 2011 Oct 30; 155(2):317-25. PubMed ID: 21699929
    [Abstract] [Full Text] [Related]

  • 20. A new oncolytic adenoviral vector carrying dual tumour suppressor genes shows potent anti-tumour effect.
    Liu XR, Cai Y, Cao X, Wei RC, Li HL, Zhou XM, Zhang KJ, Wu S, Qian QJ, Cheng B, Huang K, Liu XY.
    J Cell Mol Med; 2012 Jun 30; 16(6):1298-309. PubMed ID: 21794078
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.